Financière de Tubize S.A.
TUB
株式のランク
#2124
Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a... Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a global biopharmaceutical firm, primarily through its investment in UCB. The company is dedicated to discovering and advancing innovative medicines and solutions focused on neurological and immunological disorders. Its current commercial offerings include Cimzia, an established treatment for a range of inflammatory conditions such as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For partial-onset seizures in epilepsy, it provides Briviact, Vimpat, and Keppra, alongside Nayzilam, a nasal spray. Neupro addresses Parkinson's disease and restless legs syndrome. Additionally, the portfolio features Evenity, an injectable therapy for osteoporosis, and Bimzelx, used to manage moderate to severe plaque psoriasis. The company's development pipeline highlights several promising candidates: Staccato, aimed at stereotypical prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Other therapies under investigation include bimekizumab, which targets psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab, for conditions like myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol, intended for systemic lupus erythematosus.
株価
$217.30
時価総額
$9.67B
変化（1日）
-0.97%
変化（1年）
-20.11%
国
BE
取引 Financière de Tubize S.A. (TUB)
カテゴリー
Healthcare
Financière de Tubize S.A.（TUB）の配当利回りの履歴
Financière de Tubize S.A.（銘柄コード: TUB）の配当利回り（TTM）は2023-12-31時点で1.20%です。
過去5年間の平均配当利回り: 0.89%
過去5年間の平均配当利回り: 0.89%
Financière de Tubize S.A.（TUB）の2003から2026までの配当利回りの履歴
各年末時点の配当利回り（TTM）
| 年 | 配当利回り | 変化 |
|---|---|---|
| 2026 (TTM) | 0.65% | -4.41% |
| 2024 | 0.68% | -43.33% |
| 2023 | 1.20% | 13.21% |
| 2022 | 1.06% | 41.33% |
| 2021 | 0.75% | 0.00% |
| 2020 | 0.75% | -14.77% |
| 2019 | 0.88% | -1.12% |
| 2018 | 0.89% | 12.66% |
| 2017 | 0.79% | -5.95% |
| 2016 | 0.84% | 18.31% |
| 2015 | 0.71% | -21.98% |
| 2014 | 0.91% | -10.78% |
| 2013 | 1.02% | -31.54% |
| 2012 | 1.49% | -24.75% |
| 2011 | 1.98% | -9.59% |
| 2010 | 2.19% | 10.61% |
| 2009 | 1.98% | -45.30% |
| 2008 | 3.62% | 146.26% |
| 2007 | 1.47% | 75.00% |
| 2006 | 0.84% | 154.55% |
| 2005 | 0.33% | -73.60% |
| 2004 | 1.25% | -19.35% |
| 2003 | 1.55% | 0.00% |
類似企業または競合他社の配当利回り（TTM）
| 企業 | 配当利回り | 国 |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
